Private & confidential
Dr. Lin Lizhu
Chinese name: 林丽珠
Chief Physician, Professor, Doctoral Supervisor, Vice President . TCM Oncology
Professor Lin Lizhu is Vice President of the First Affiliated Hospital of Guangzhou University of Chinese Medicine and academic leader of national key TCM oncology. A disciple of National Master Zhou Daihan, she specialises in integrated Chinese and Western medicine for advanced tumours, especially lung cancer, and has led more than forty national research projects.
nearly 40 years
Clinical practice in traditional Chinese medicine oncology
over 100,000
Cancer patients diagnosed and treated
400+ papers
Academic papers published, including SCI-indexed
About Dr. Lin Lizhu
Professor Lin Lizhu is Vice President of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, academic leader of the national key TCM oncology specialty, and head of the oncology clinical trial unit. A disciple of National Master Zhou Daihan, she has practised integrated Chinese and Western medicine for cancer for more than thirty years, specialising in advanced malignant tumours, especially lung cancer, liver cancer and lymphoma. She has led over forty national and provincial research projects, taken part in more than sixty clinical trials, published four hundred papers including seventy SCI papers, edited more than twenty books and developed the hospital preparation Yifei Sanjie Pill. She holds the titles National Advanced Worker and Guangdong Famous TCM Doctor.
1、Vice President of the First Affiliated Hospital of Guangzhou University of Chinese Medicine
2、Academic leader of the national key TCM oncology specialty
3、Head of the national drug clinical trial oncology unit
4、Recipient of the title National Advanced Worker and delegate to the 19th National Congress of the CPC
5、Guangdong Famous TCM Doctor and medical leading talent of Guangdong Province
6、Recipient of the Guangdong Provincial Science and Technology First Prize and the Ministry of Education Science and Technology First Prize
7、Editor-in-chief of more than twenty books on integrated cancer treatment
Dr. Lin Lizhu ’s Three Key Areas of Expertise
Three areas of focused expertise, each supported by a deep subspecialty team, high case volumes and an English-speaking care pathway coordinated by Orisene.
Advanced lung cancer
She treats advanced lung cancer with integrated Chinese and Western medicine, combining the hospital preparation Yifei Sanjie Pill and individualised herbal formulae with chemotherapy, targeted therapy and immunotherapy to control tumour growth, relieve symptoms and extend survival for patients with late-stage disease.
Liver cancer and lymphoma
She manages primary liver cancer and malignant lymphoma using syndrome-differentiation herbal therapy together with conventional treatment, aiming to protect liver function, reduce treatment toxicity and enhance immunity for patients with these difficult cancers in routine clinical practice and improve their quality of life.
Colorectal and nasopharyngeal cancer
She provides integrated Chinese and Western medicine for colorectal, nasopharyngeal and gynaecological tumours, using individualised herbal prescriptions to reduce radiotherapy and chemotherapy side effects, support nutrition and immunity and improve the comfort of patients during long-term cancer treatment in routine care.
More：lung cancer——integrated therapy; liver cancer——comprehensive care; lymphoma——herbal treatment; colorectal cancer——supportive care; gynaecological tumours——management
Selected cases, research & publications
Representative work drawn from documented clinical treatments, publicly indexed literature, and hospital project records, reflecting the depth of this physician's hands-on expertise and academic rigor.
1. Yifei Sanjie Pills for non-small cell lung cancer
Yifei Sanjie Pills are a hospital preparation developed by Professor Lin Lizhu for patients with non-small cell lung cancer. A real-world study evaluated their use together with targeted therapy, aiming to shrink tumors, reduce cough and fatigue, and improve quality of life in lung cancer patients receiving EGFR-TKI treatment.
2. Patterns of Chinese herbal medicine in lung cancer treatment
Professor Lin Lizhu has studied the patterns of Chinese herbal prescriptions used to treat lung cancer, comparing treatment approaches in northern and southern China. Her research helps clinicians select herbs that strengthen the body, clear toxins and relieve symptoms, offering a reference for integrating traditional medicine into modern lung cancer care.
Related link: https://pubmed.ncbi.nlm.nih.gov/21866673/
3. Quality-of-life evaluation system for cancer patients
Professor Lin Lizhu established a quality-of-life evaluation system for cancer patients treated with traditional Chinese medicine, allowing clinicians to measure how herbal therapy affects appetite, sleep, pain and daily activity. This framework has been applied in clinical trials of integrated treatment for lung, liver and colorectal cancer.
Related link: https://www.gzucm.edu.cn/info/1091/107111.htm
4. Integrated treatment of advanced liver cancer
Professor Lin Lizhu treats patients with advanced liver cancer using integrated Chinese and Western medicine, combining herbal formulas with transarterial chemoembolization and targeted drugs. Her approach focuses on controlling tumor growth, protecting liver function and easing abdominal pain, jaundice and fatigue in patients who are not candidates for surgery.
5. Traditional Chinese medicine for lung cancer after chemotherapy
This clinical program uses Chinese herbal medicine to help lung cancer patients recover after chemotherapy and radiotherapy. Professor Lin Lizhu’s team focuses on reducing fatigue, improving blood counts and controlling cough, helping patients complete more treatment cycles and maintain a better daily life during cancer therapy.
6. Specialized oncology outpatient clinic for cancer patients
Professor Lin Lizhu runs a specialized traditional Chinese medicine oncology clinic for patients with lung, liver and colorectal cancer, as well as breast and nasopharyngeal cancer. She provides personalized herbal treatment, follow-up care and dietary guidance to help patients control symptoms and improve survival and quality of life.
Where Dr. Lin Lizhu practices
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Chinese name: 广州中医药大学第一附属医院
Founded in 1964, the First Affiliated Hospital of Guangzhou University of Chinese Medicine is one of China's first Grade-A tertiary TCM hospitals. With 2,200 beds and 3.19 million annual visits, it is renowned for TCM gastroenterology, orthopedics and gynecology, led by national masters of Chinese medicine.
62 years of TCM care
Since 1964
2,200
Licensed beds
3.19 million
Annual outpatient & emergency visits
7
Licensed beds
Appointments with this physician are booked through official hospital channels only, coordinated end-to-end by Orisene.
Why patients travel to China for treatment
Six reasons international patients now put China on their shortlist — from internationally aligned clinical capability to the policy channels that make treatment here genuinely reachable.
Clinical capability at international standard
Chinese hospitals deliver internationally aligned protocols, performing vast volumes of advanced robotic, minimally invasive, and complex transplant surgeries annually. This massive clinical data and highly specialized workforce ensure world-class outcomes, even for rare and complex cases.
Diagnostics and treatment in days, not months
A full medical workup that typically means months of waiting elsewhere is completed in China within 48–72 hours. Imaging, labs, and multidisciplinary consultations are integrated into a single visit, allowing treatment to commence immediately.
Transparent, itemised pricing
Chinese healthcare offers legally binding, itemised cost estimates before treatment begins, eliminating hidden fees or surprise billing. Due to national centralized procurement, total expenses remain 40–70% lower than comparable care in Western Europe or North America.
Policy channels that open the door
China facilitates access through 240-hour visa-free transit and dedicated medical visa routes. Policies like the Greater Bay Area drug pathway and Boao Lecheng’s pilot zone allow designated hospitals to administer innovative therapies not yet globally approved.
Consulting this physician, step by step
From the first message to the follow-up after you fly home, one coordinator, no paperwork on your side.
01
Day 0
- Share your storyA private consultation with an Orisene advisor, by message, phone or video. Send medical records in any language. Nothing is shared with the hospital yet.
02
Days 1–3
- Records review & matchingOrisene translates and presents your case to the right specialist. The hospital returns a tailored care plan, with costs itemised once that plan is confirmed.
03
Days 3–7
- Your consultationAppointments are booked through official hospital channels only. Your navigator accompanies every visit with real-time interpretation, so you can focus on one thing: being cared for.
04
After you fly home
- Reports & follow-upTranslated reports and prescriptions delivered within days, remote follow-up coordination with your physicians at home, and a standing line to your navigator.
Orisene offers English and multilingual services, a professional medical interpreter at every consultation, plus translation of your records, reports and prescriptions.
Ready to plan your consultation with Dr. Lin Lizhu?
Send your records in any language. An Orisene advisor will reply within 2 hours, present your case to the right specialist, and return a tailored care plan with itemised costs, before anything is booked. Simple. Private. Efficient.
Information Sources
This physician profile is compiled by the Orisene team from publicly available online sources and verified at the time of publication. Details may change, and physician availability is confirmed at the time of booking.
- Guangzhou University of Chinese Medicine First Affiliated Hospital Official Expert Page: https://www.gztcm.com.cn/myzl/myhc/1hbaaufp149ql.shtml
- PubMed Author Records (integrated cancer treatment): https://pubmed.ncbi.nlm.nih.gov/24382781/
- PubMed Author Records (TCM for lung cancer): https://pubmed.ncbi.nlm.nih.gov/16398422/
Disclaimer: This information is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personal medical guidance.
Mention of any specific product, brand, or manufacturer is for informational purposes only and does not constitute an endorsement or recommendation by Dr. Lin Lizhu.